File photo shows Kuomintang Honorary Chairman Lien Chan leaves Peking University with his wife Lien Fang-yu during their visit in Beijing in 2014. [Photo/China Daily] The upcoming visit of Lien Chan, former chairman of the Chinese Kuomintang in Taiwan, to Beijing next week shows a gesture to ease tensions across the Taiwan Straits, a scholar said on Friday. Lien will lead a delegation to visit the mainland from July 12 to 14, An Fengshan, spokesman for the State Council Taiwan Affairs Office, announced on Friday. Following the stop in Beijing, the delegation will visit Liaoning, Jilin and Zhejiang provinces, he said. Lien is also chairman of a foundation on cross-Straits peaceful development. According to Taiwan media, the delegation has about 50 powerful figures from the island, including Terry Guo, founder and chairman of Foxconn, the world's largest contract electronics manufacturer and major suppler for Apple. Lien's visit comes amid rising tension between the mainland and Taiwan, as Taiwan leader Tsai Ing-wen has failed to recognize the 1992 Consensus, which embodies the one-China principle, and her right-hand man, the island's executive head Lai Ching-te, publicly called himself a Taiwan independence worker. Scholars have noted that Tsai's recent behavior, such as calling on the international community to constrain the Chinese mainland, courting foreign support and creating hostility among people from the mainland and Taiwan, will enhance confrontation in cross-Straits relations. Wang Hailiang, a Taiwan studies researcher at the Shanghai Academy of Social Sciences, said Lien's coming visit is more likely a symbolic gesture that shows Lien's stance to help ease the tension between the mainland and Taiwan. But Lien is no longer the leader of the KMT and the impact of his visit may be limited, Wang said. Lien, who retired as KMT chairman in August 2005, has been an important figure in the history of the relationship between the Communist Party of China and KMT, and in the history of cross-Straits relations. In April 2005, as then KMT leader, he visited the Chinese mainland and met Hu Jintao, then general secretary of the CPC Central Committee, breaking the ice that had existed for half a century. It was the first meeting for leaders of the two parties since 1949. After that, Lien visited the mainland a dozen times, and met general secretary of the CPC Central Committee Xi Jinping in 2013, 2014 and 2015. support braceletsmotivational bracelets for athletesrubber arm bandswristbands online24 wristbandsblack rubber wristbands
The State Administration for Food and Drug has approved simultaneous port inspection and market sales of Herceptin, the Shanghai Municipal Food and Drug Administration told thepaper.cn Monday.The move saves two to three months from the time required for the drug to reach the hands of customers amid a shortage in the domestic market.Herceptin is a targeted therapy for HER2 positive metastatic breast cancer and HER2 positive gastric cancer. Patients who lack the drug might not recover or could risk shortening their lives.In July 2017, Herceptin was included in the National Reimbursement Drug List. The market price of the drug, which was marked 19,800 yuan ($3,092) for an injection before the inclusion, dropped 60 percent to 7,600 yuan.As the national reimbursement scheme can cover 70 to 80 percent of the drug's cost in most regions, meaning a customer can buy Herceptin at 1,500 yuan for an injection, demand for the drug skyrocketed.Swiss-based drug maker Roche Holding AG, the producer and sole supplier of Herceptin in China's market, said on May 31 that the company has taken several measures to deal with the shortage, including implementing the China market priority strategy, raising the production capacity to full steam, and optimizing logistics channels.The company also filed an application with the State Administration for Food and Drug, asking to relocate the production of Herceptin from its current base to a new one with a higher production capacity. The application was approved May 30.Despite the measures, the company said as it takes longer for production and inspection of the drug, and also time for import and inspection by Chinese authorities before entering the market, it still needs time to fully meet the demand.
